Print Page   |   Sign In   |   Join MAA
News & Press: News

What’s new for 2017 for Meningococcal vaccination?

Wednesday, March 8, 2017   (0 Comments)
Posted by: David Waldrep
Share |

By Sandra Adamson Fryhofer MD 


Here’s what’s new for 2017.  There are new indications for MenACWY vaccination  and new dosing recommendations for one of the Men B vaccines .


The details are in the footnotes of the new 2017 ACIP Adult Immunization that has now been released.  It’s published in the Annals of Internal Medicine.  Download a copy at: Abstract:  


Here’s a preview:  HIV infected patients should be given a two dose series of the MenACWY meningococcal conjugate vaccine (and revaccination every 5 years).  However, Men B vaccination for those with HIV infection is not routinely recommended.


Last year, the 2016 schedule introduced two new meningococcal B vaccines.  ACIP still says either is fine to use. But there is some clarification about the number of doses needed for MenB- FHbp vaccine- brand name, Trumenba.  Only two doses are now recommended for routine vaccination of healthy adolescents and young adults.  But during an outbreak, 3 doses are still needed.  No dosing changes were made for other Men B vaccine, MenB- 4C, brand name Bexsero- 2 dose series.


This year’s footnote has bullets for recommendations according to medical condition, workplace exposure, exposure during an outbreak, as well as indications for international travelers.  It also includes specific recommendations for younger adults.  For example, first year college students need a dose MenACWY vaccination at 16 or older.   Young adults age 16-23 may receive 2 dose of either Men B vaccine for short term protection.   Remember that the two different Men B vaccines are NOT interchangeable.  The same vaccine must be used for all doses in the series. MenACWY and Men B vaccines can be given at the same time as long as they are given at different anatomical sites. 

Association Management Software Powered by YourMembership  ::  Legal